Azenta’s Mixed Performance: Growth in Multiomics Amidst US Market Challenges Leads to Hold Rating

Analyst Brendan Smith from TD Cowen maintained a Hold rating on Azenta and keeping the price target at $35.00.

Brendan Smith has given his Hold rating due to a combination of factors affecting Azenta’s performance. The company has shown positive growth in certain areas, such as a notable increase in Multiomics revenue, particularly in the European and Chinese markets. This growth has been driven by strong sequencing volume and gene synthesis, which has helped offset weaknesses in other segments.
However, despite these positive developments, there are concerns that temper the overall outlook. The slowdown in spending within the US market, partly due to macroeconomic factors and government shutdowns, has impacted Azenta’s SMS revenue. Additionally, while restructuring efforts are expected to improve EBITDA margins, the overall revenue growth guidance for FY26 remains modest. These mixed signals contribute to the Hold rating, as the potential for growth is balanced by significant challenges.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZTA in relation to earlier this year.